Ubretid - Instructions For Use, Price, Analogues, Reviews

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Ubretid

Ubretid: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Drug interactions
11. 11. Analogs
12. 12. Terms and conditions of storage
13. 13. Terms of dispensing from pharmacies
14. 14. Reviews
15. 15. Price in pharmacies

Latin name: Ubretid

ATX code: N07AA03

Active ingredient: distigmine bromide (distigmine bromide)

Manufacturer: Nycomed Austria (Austria)

Description and photo update: 2018-21-11

Ubretid is an anticholinesterase agent.

Release form and composition

Dosage forms of Ubretid:

• tablets: white, marked "UB" and "5.0" on one side (10 pcs. in blisters, in a cardboard box 2 or 5 blisters);
• solution for injection: transparent (1 ml in ampoules, in a carton box of 3, 5 or 25 ampoules).

Composition of 1 tablet:

• active substance: distigmine bromide - 5 mg;
• auxiliary components: corn starch, talc, glucose, magnesium stearate.

Composition of 1 ml solution:

• active substance: distigmine bromide - 0.5 or 1 mg;
• auxiliary components: sodium chloride, water for injection.

Pharmacological properties

Pharmacodynamics

Dystigmine bromide is a substance that inhibits acetylcholinesterase in the synaptic cleft, which contributes to the accumulation of acetylcholine and the prolongation of its action. As a result of this action, secretion increases, the tone of the bladder, gastrointestinal tract and skeletal muscles increases.

Ubretid causes moderate vasodilation, slows down the heart rate. Does not significantly affect the transmission of impulses in the autonomic nervous system.

The effect of the drug is manifested 1 hour after administration in the form of increased secretion, increased tone and motility of the intestines, bladder and ureters. The maximum increase in the tone of the gastrointestinal tract is noted after 8-10 hours and lasts for 20 hours.

A pronounced effect with myasthenia gravis is observed after 1-2 days.

Pharmacokinetics

Dystigmine bromide does not penetrate the blood-brain barrier, therefore it does not affect acetylcholine in the central nervous system.

The bioavailability of the drug is 4.7%. It is metabolized by hydrolysis with the formation of metabolites, which are excreted in the urine.

Compared with other anticholinesterase drugs, distigmine bromide has a more stable binding to acetylcholinesterase and a longer excretion in the urine.

Indications for use

• megacolon;
• chronic hypotonic and atonic constipation;
• postoperative atony and paralytic intestinal obstruction (treatment and prevention);
• functional insufficiency of the sphincter of the bladder and hypotension of the bladder (including neurogenic bladder);
• postoperative atony of the bladder and ureters;
• severe myasthenia gravis (myasthenia gravis);
• peripheral paralysis of striated muscles.

Contraindications

• profuse salivation;
• hypermotility of the gastrointestinal tract;
• hyperacidity of gastric juice;
• hypertonicity of the intestines, biliary and urinary tract;
• inflammatory bowel disease;
• stomach ulcer;
• severe vagotonia (predominance of the tone of the parasympathetic nervous system) with manifestations of severe bradycardia;
• arterial hypotension;
• chronic heart failure;
• postoperative vascular crisis;
• peripheral circulatory disorders;
• myocardial infarction;
• tetany;
• increased muscle tone;
• parkinsonism;
• epilepsy;
• bronchial asthma;
• hypersensitivity to bromine or drug components.

Instructions for the use of Ubretid: method and dosage

The Ubretid tablets are taken orally, 1 time per day, in the morning on an empty stomach, with a little water. The starting dose is 5 mg. If necessary, after a week, the dose is increased to 10 mg per day or reduced to 5 mg every 2-3 days.

The Ubretid solution is administered intramuscularly. A single dose is 0.5 mg. Re-introduction is possible in a day, in the future, 2-3-day breaks are made between injections. If necessary, the dose is increased to 0.1 mg for every 10 kg of body weight.

Dosing according to special indications:

• myasthenia gravis: 0.5-0.75 mg with an interval of 2 days;
• megacolon, hypotonic chronic stool retention: 0.5 mg 2 times a week;
• postoperative atony of the bladder and ureters: 0.5 mg each 36–48 hours after surgery (usually in the morning on the second day after surgery). If necessary, the dose is increased to 0.1 mg per 10 kg of body weight and the drug is prescribed every 3 days for a course of 27 days. In case of postoperative X-ray irradiation, it is recommended to take Ubretid tablets, 5 mg per day, before the end of the therapeutic course;
• postoperative intestinal atony: 0.5 mg each 24–72 hours after surgery. If necessary, the dose is increased to 0.1 mg per 10 kg of body weight. After 1-3 days, the drug is re-injected at the same dose;
• functional insufficiency of the sphincter of the urinary bladder: initial dose - 0.5 mg. If required, the dose is increased to 0.1 mg per 10 kg of body weight and administered every 3-4 days until the desired effect is achieved, then the patient is transferred to Ubretid tablets.

Side effects

Uretid may cause the following side effects: difficulty swallowing, diarrhea, nausea, vomiting, intestinal cramps, increased intestinal motility or gastric motility, pupillary constriction, muscle spasms, lacrimation, bronchospasm, hypersalivation, increased sweating, tremor, bradycardia / min (less than 60 strokes) and other manifestations of hyperexcitation of m- and n-cholinergic receptors.

Overdose

In case of an overdose, symptoms are noted due to the cholinomimetic effect of distigmine bromide, including diarrhea, abdominal pain, nausea, vomiting, torrential sweat, bronchospasm, miosis, bradycardia, etc.

Intravenous or subcutaneous administration of atropine (0.5–1 mg) is recommended as an antidote.

special instructions

The drug should be used with caution in the treatment of women with temporary dysmenorrhea, as it can cause menstrual bleeding.

If, after taking the Ubretid tablets, the effect did not appear due to the simultaneous or previous meal, the drug should not be taken again for several hours, since the accumulation of dystigmine bromide is possible.

Influence on the ability to drive vehicles and complex mechanisms

According to the instructions, Ubretide can reduce the speed of reactions, therefore, during treatment, it is recommended to refrain from driving and performing work that requires the speed of psychophysical reactions.

Application during pregnancy and lactation

Ubretid can be used during pregnancy and during breastfeeding only if there is a strict indication.

Drug interactions

The action of Ubretid is weakened by curariform, antihistamines, psychotropic and anticholinergic drugs, as well as aminoglycosides.

Analogs

There is no information about Ubretid's analogues. A similar mechanism of action is possessed by the drugs Amiridin, Aminostigmin, Neuromidin, Proserin, Axamon, Kalimin.

Terms and conditions of storage

Store tablets in a dry place at a temperature of 15 to 25 ° С, solution for injection - at a temperature of 2–8 ° С (in the refrigerator). Keep out of the reach of children.

The shelf life is 5 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Ubretid

According to reviews, Ubretid effectively improves neuromuscular conduction, and therefore is most often used to treat myasthenia gravis. It has a cumulative property, so some doctors prescribe it with caution, carefully choosing the required dose.

From the side of patients taking Ubretid, there are conflicting reviews. Some indicate a significant improvement in the condition during therapy, others complain of the development of side effects, including abdominal pain, dyspepsia, and cholinergic crisis.

Price for Ubretid in pharmacies

The price of Ubretid is unknown, since the drug has not been registered in the Russian Federation to date.

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!